Article

Co-targeting BCL-X <sub>L</sub> and MCL-1 with DT2216 and AZD8055 synergistically inhibits small-cell lung cancer growth without causing on-target toxicities in mice

2022-09-14

Abstract excerpt

<h4>ABSTRACT</h4> Small-cell lung cancer (SCLC) is an aggressive malignancy with limited therapeutic options. The dismal prognosis in SCLC is in part associated with an upregulation of BCL-2 family anti-apoptotic proteins, including BCL-X L and MCL-1. Unfortunately, the currently available inhibitors of BCL-2 family anti-apoptotic proteins, except BCL-2 inhibitors, are not clinically relevant because of various...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 31487ba7-6b63-54a4-8a4a-a3c003d25838
DOI: 10.1101/2022.09.12.507616

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Co-targeting BCL-X <sub>L</sub> and MCL-1 with DT2216 and AZD8055 synergistically inhibits small-cell lung cancer growth without causing on-target toxicities in miceDOI 10.1101/2022.09.12.507616Read

MCL1 inhibition is effective against a subset of small-cell lung cancer with high MCL1 and low BCL-XL expressionSemantic proximity Read

Dual inhibition of BCL2L1 and MCL1 is highly effective against RET fusion-positive or MET exon 14 skipping mutation-positive lung adenocarcinoma cells.Semantic proximity Read

Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancerSemantic proximity Read

Venetoclax Is Effective in Small-Cell Lung Cancers with High BCL-2 ExpressionSemantic proximity Read

Influence of Bcl-2 Family Members on the Cellular Response of Small-Cell Lung Cancer Cell Lines to ABT-737Semantic proximity Read

Overcoming multi-drug resistance in SCLC: a synergistic approach with venetoclax and hydroxychloroquine targeting the lncRNA LYPLAL1-DT/BCL2/BECN1 pathwaySemantic proximity Read

Malignant pleural mesothelioma co-opts BCL-XL and autophagy to escape apoptosisSemantic proximity Read

Therapeutic Efficacy of ABT-737, a Selective Inhibitor of BCL-2, in Small Cell Lung CancerSemantic proximity Read

Dual targeting of BCL-XL and MCL-1 exposes a rapid and exploitable apoptotic vulnerability in non-small cell lung cancerSemantic proximity Read

DCZ0014, A Novel Compound in the Therapy of Diffuse Large B-Cell Lymphoma via the B Cell Receptor Signaling PathwaySemantic proximity Read

JQ1 synergizes with the Bcl-2 inhibitor ABT-263 against MYCN-amplified small cell lung cancerSemantic proximity Read

Inhibition of PI3K/BMX Cell Survival Pathway Sensitizes to BH3 Mimetics in SCLCSemantic proximity Read